Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.

Tytuł:: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
Autorzy:: McAnena PF; Discipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
McGuire A; Discipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
Ramli A; Discipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
Curran C; Discipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
Malone C; Discipline of Surgery, Galway University Hospital, Galway, Ireland.
McLaughlin R; Discipline of Surgery, Galway University Hospital, Galway, Ireland.
Barry K; Discipline of Surgery, Galway University Hospital, Galway, Ireland.
Brown JAL; Discipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland. .
Kerin MJ; Discipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
Źródło:: BMC cancer [BMC Cancer] 2018 Feb 20; Vol. 18 (1), pp. 203. Date of Electronic Publication: 2018 Feb 20.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: London : BioMed Central, [2001-
References:: Ann Oncol. 2009 Dec;20(12):1953-8. (PMID: 19596702)
Br J Cancer. 2005 Sep 5;93(5):552-6. (PMID: 16106267)
BMJ. 2016 Jun 23;353:i3256. (PMID: 27339037)
Breast Cancer Res. 2010;12(5):R75. (PMID: 20863372)
Breast Cancer Res. 2000;2(6):400-7. (PMID: 11250733)
Oncologist. 2008 Nov;13(11):1134-6. (PMID: 18987048)
Ann Oncol. 2013 Dec;24(12):3017-23. (PMID: 24114857)
Nature. 2011 Apr 7;472(7341):90-4. (PMID: 21399628)
Breast J. 1999 Nov;5(6):369-374. (PMID: 11348316)
Hum Pathol. 2012 Mar;43(3):398-404. (PMID: 21840040)
Clin Breast Cancer. 2004 Apr;5(1):63-9. (PMID: 15140287)
J Vasc Interv Radiol. 2010 Jul;21(7):969-75. (PMID: 20304676)
J Clin Oncol. 2012 Jul 20;30(21):2601-8. (PMID: 22711854)
Nature. 2002 Aug 22;418(6900):823. (PMID: 12192390)
J Clin Oncol. 2012 Feb 20;30(6):587-92. (PMID: 22124102)
Cancer Metastasis Rev. 2016 Sep;35(3):427-37. (PMID: 27405651)
J Biol Chem. 2009 Jul 3;284(27):18515-24. (PMID: 19419954)
N Engl J Med. 2016 Nov 17;375(20):1993-1994. (PMID: 27959592)
Int J Cancer. 2008 Mar 1;122(5):999-1004. (PMID: 17973263)
Endocr Relat Cancer. 2004 Sep;11(3):497-522. (PMID: 15369451)
Nature. 2009 Oct 8;461(7265):809-13. (PMID: 19812674)
Mod Pathol. 1998 Feb;11(2):155-68. (PMID: 9504686)
Med Hypotheses. 2005;64(6):1182-7. (PMID: 15823713)
J Clin Oncol. 1999 Jul;17(7):1983-7. (PMID: 10561248)
J Clin Oncol. 2015 Aug 20;33(24):2695-704. (PMID: 26195705)
Cancer Cell. 2007 Mar;11(3):259-73. (PMID: 17349583)
Eur J Cancer. 2014 Jan;50(2):277-89. (PMID: 24269135)
Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029)
Cancer Treat Rev. 2012 Oct;38(6):708-14. (PMID: 22178456)
Ann Oncol. 2009 Sep;20(9):1499-504. (PMID: 19299408)
Lancet. 2005 May 14-20;365(9472):1687-717. (PMID: 15894097)
Cancer. 2011 Feb 15;117(4):705-13. (PMID: 20939012)
Oncotarget. 2015 Oct 20;6(32):33306-18. (PMID: 26375671)
Breast Cancer Res. 2016 Jun 28;18(1):68. (PMID: 27349894)
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815)
BMC Cancer. 2012 Nov 24;12:555. (PMID: 23176370)
Ann Oncol. 2013 Jan;24(1):101-8. (PMID: 23002281)
Clin Breast Cancer. 2016 Aug;16(4):e133-40. (PMID: 27268749)
Adv Exp Med Biol. 2008;617:485-91. (PMID: 18497073)
Breast Cancer Res. 2010;12(6):R92. (PMID: 21059212)
Contributed Indexing:: Keywords: Breast cancer; Discordance; Post-recurrence survival; Subtype; Triple negative
Entry Date(s):: Date Created: 20180222 Date Completed: 20180827 Latest Revision: 20181113
Update Code:: 20240105
PubMed Central ID:: PMC5819681
DOI:: 10.1186/s12885-018-4101-7
PMID:: 29463223
: Czasopismo naukowe

Pełny tekst

Background: Recent studies have shown that breast cancer subtype can change from the primary tumour to the recurrence. Discordance between primary and recurrent breast cancer has implications for further treatment and ultimately prognosis. The aim of the study was to determine the rate of change between primary and recurrence of breast cancer and to assess the impact of these changes on survival and potential treatment options.
Methods: Patient demographics were collected on those who underwent surgery for breast cancer between 2001 and 2014 and had a recurrence with biopsy results and pathology scoring of both the primary and recurrence.
Results: One hundred thirty two consecutive patients were included. There were 31 (23.5%) changes in subtype. Discordance occurred most frequently in luminal A breast cancer (n = 20), followed by triple negative (n = 4), luminal B (n = 3) and HER2 (n = 3). Patients who changed from luminal A to triple negative (n = 18) had a significantly worse post-recurrence survival (p < 0.05) with overall survival approaching significance (p = 0.064) compared to concordant luminal A cases (n = 46). Overall receptor discordance rates were: estrogen receptor 20.4% (n = 27), progesterone receptor 37.7% (n = 50) and HER2 3% (n = 4). Loss of estrogen receptor and progesterone receptor was more common than gain (21 vs. 6 (p = 0.04) and 44 vs. 6 (p = 0.01) respectively). Nine patients (6.8%) gained receptor status potentially impacting treatment options.
Conclusion: Discordance in subtype and receptor status occurs between primary and recurrent breast cancer, ultimately affecting survival and potentially impacting treatment options.

Erratum in: BMC Cancer. 2018 Mar 13;18(1):282. (PMID: 29534688)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja